Allen Jeremias, MD
Cardiovascular Disease · E Setauket, NYNPI 1427138395
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 18.7%. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $993.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$123K
- Shockwave Medical, Inc$121K
- Novo Nordisk$94K
- Philips North America LLC$81K
- Boston Scientific$67K
- Acist Medical Systems, Inc.$65K
- plus $106K from 31 others
Across 15 payments — averaging $9888.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$119K
- E.r. Squibb & Sons, L.L.C.$25K
- Medtronic$4K
- Abbott$473
Across 2 payments — averaging $100,356 each. An ownership or investment interest held by the physician or an immediate family member.
- Spectrawave, Inc$201K
What the payments were for
- Consulting fees$260,98840%
- Speaking & faculty fees$313,22548%
- Grants$5000%
- Travel & lodging$54,8928%
- Food & beverage$28,1804%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 172 | $123,222 |
| Shockwave Medical, Inc | 48 | $120,682 |
| Novo Nordisk | 70 | $94,321 |
| Philips North America LLC | 77 | $80,949 |
| Boston Scientific | 67 | $67,308 |
| Acist Medical Systems, Inc. | 35 | $64,863 |
| Cathworks, Inc. | 17 | $28,933 |
| AstraZeneca | 43 | $27,187 |
| E.r. Squibb & Sons, L.L.C. | 20 | $15,085 |
| Siemens Medical Solutions USA, Inc. | 8 | $8,538 |
| Abiomed | 8 | $6,496 |
| Neovasc Medical Inc | 6 | $4,415 |
| ZOLL Circulation Inc | 3 | $3,767 |
| Recor Medical Inc | 7 | $3,536 |
| Medtronic(2 entities) | 20 | $2,064 |
| Biotronik Inc. | 4 | $1,373 |
| Cordis US CORP. | 4 | $1,373 |
| Cardiovascular Systems Inc. | 8 | $1,063 |
| Terumo Medical Corporation | 3 | $821 |
| Johnson & Johnson | 7 | $324 |
| Esperion Therapeutics, Inc. | 5 | $197 |
| Penumbra, Inc. | 1 | $142 |
| Boehringer Ingelheim | 2 | $141 |
| Regeneron | 1 | $130 |
| Arrow International, Inc. | 1 | $118 |
| Amgen | 5 | $101 |
| Edwards Lifesciences | 2 | $96 |
| Asahi Intecc USA, Inc. | 1 | $86 |
| Novartis | 4 | $80 |
| Spectrawave, Inc | 1 | $80 |
| Kestra Medical Technology Services, Inc. | 2 | $78 |
| Tactile Systems Technology Inc | 2 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Inari Medical, Inc. | 2 | $46 |
| Impulse Dynamics (USA) Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$113,220
- Ozempic$65,395
- Xience V coronary stent system$62,863
- HD-IVUS$56,728
- (9520) IGT Devices Undivided$47,016
- GENERAL VASCULAR ACCESS$34,750
- FFRangio$28,882
- OPTIS$17,404
- RYBELSUS$16,944
- BRILINTA$16,435
- CAMZYOS$14,660
- S-Series SCS Leads$13,500
- (BQ9) Coronary IVUS$12,378
- FARXIGA$10,344
- Omnilink Elite vascular stent system$7,994
- ISOVUE$7,650
- AVVIGO Guidance System$6,919
- Vascular Lithotripsy$6,868
- Spectranetics Undiv$6,400
- Impella$6,112
How this compares
$657,786 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $147,484 |
| EntrestoSacubitril/Valsartan | 93 | $119,778 |
| CamzyosMavacamten | 14 | $112,961 |
| XareltoRivaroxaban | 63 | $73,923 |
| FarxigaDapagliflozin Propanediol | 48 | $50,536 |
| MultaqDronedarone Hcl | 25 | $41,008 |
| OzempicSemaglutide | 31 | $33,833 |
| NexlizetBempedoic Acid/Ezetimibe | 26 | $29,486 |
| BrilintaTicagrelor | 28 | $29,197 |
| Repatha SureclickEvolocumab | 31 | $27,014 |
| Praluent PenAlirocumab | 29 | $18,122 |
| Prasugrel Hcl | 58 | $5,261 |
| VascepaIcosapent Ethyl | 12 | $4,941 |
| Valsartan | 158 | $4,392 |
| Metoprolol Succinate | 193 | $3,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $80 | $119,77893 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $15,085 | $112,96114 claims |
| AstraZenecaFarxiga, Brilinta | $27,187 | $79,73276 claims |
| Johnson & JohnsonXarelto | $324 | $73,92363 claims |
| Sanofi-aventis U.S. LLCMultaq | $48 | $41,00825 claims |
| Novo NordiskOzempic | $94,321 | $33,83331 claims |
| Esperion Therapeutics, Inc.Nexlizet | $197 | $29,48626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in E Setauket
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.